Betalin was founded to promote the development of the EMP as a novel islets’ transplantation therapy, Betalin plan is that our treatment could replace current NHS protocol, and help patients suffering from Diabetes to achieve normoglycaemia.
Diabetes is an ongoing and constantly growing concern in the developed world. Patients with Diabetes suffer from lack of insulin production. Insulin is a crucial hormonal “key” which allows glucose to enter red blood cells (haemoglobin) and be metabolised properly by the body. Without it, glucose remains in the blood and causes significant complications that can be both short term - seizures and fainting that could result in coma or even death, and long-term - stroke, heart disease, blindness, kidney failure and limb amputation.
Unfortunately, the most used solutions for diabetes are only managing solutions of the disease with many side effects. Lately, more and more scientist, including our own, looking for a different way to treat diabetes using cell therapy as the future therapy.
The vision of Betalin is to eliminate the need of insulin injections in diabetic patients using our technology of Micro Pancreas.
The Micro Pancreas has the following components: (1) a proprietary organ derived 3D scaffold, i.e. Micro-Organ Matrix (MOM); (2) Stem cell derived β-cells. After implantation under the skin (by injection), Micro Pancreas restores natural insulin production and blood glucose regulation, actually curing Diabetes. Micro Pancreas is a revolutionary regenerative micro-organ, based on cell therapy, that replaces the native human pancreatic endocrine function damaged in Diabetes
Micro Pancreas eliminates insulin dependency in diabetes patients, removing the need for daily and meal correlated injections, constant blood glucose monitoring and dietary constraints. Instead, patients get a biological implant by injection of Micro Pancreas, a micro-organ that generates insulin naturally in response to glucose, improving considerably day-by-day life of patients with diabetes, including children with Type 1 Diabetes and moreover, preventing the long-term complications caused by the disease.
Betalin technology outperforms contemporary standard of care solutions, such as insulin pumps or artificial pancreas that need maintenance and are cumbersome to wear, as well as islet transplantation by Edmonton Protocol, a procedure carried out by transplanting isolated islets, harvested from at least two donors, into the liver accompanied by immune suppression drugs and is used clinically today to treat most severe cases in few highly specialized medical centres. Micro Pancreas is applied by a simple procedure, not requiring hospitalization, and performed in outpatient clinics (not highly specialized hospitals).
